FDA, Regulatory Challenges Blamed
Survey: Venture Capital Drying Up for U.S. Biotech
By Catherine Shaffer
Friday, October 7, 2011
According to a report by the National Venture Capital Association's MedIC Coalition, FDA regulatory challenges, reimbursement concerns and an adverse financial environment are driving venture capital (VC) investment outside the U.S. and away from major disease areas.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.